Lupin Ltd Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension
Lupin Ltd secured tentative US FDA approval for Apixaban Oral Suspension 1.25mg/mL. The product will be manufactured at Lupin's Somerset, New Jersey facility.
Monday, 28 September 2026
NSE & BSE filings, as they land
ALFA News
Straight from the exchange filing